

Empowering rheumatology professionals to excel in their specialty

2200 Lake Boulevard NE, Atlanta, GA 30319 Phone: (404) 633-3777 • Fax (404) 633-1870 • www.rheumatology.org

## 2022 American College of Rheumatology (ACR) Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases

**Guideline Summary** 

Revised February 24, 2023

**Objective:** To provide evidence-based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases (RMDs).

Methods: This guideline follows the ACR guideline development process and ACR policy guiding management of conflicts of interest and disclosures, which includes the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methodology, and adheres to the Appraisal of Guidelines for REsearch & Evaluation (AGREE) criteria. A core leadership team consisting of adult and pediatric rheumatologists drafted clinical population, intervention, comparator, and outcomes (PICO) questions. A literature review team performed a systematic literature review for the PICO questions, graded the quality of evidence, and produced the evidence report. The evidence was reviewed, and recommendations were formulated by an expert Voting Panel that included adult and pediatric rheumatology providers, infectious diseases specialists, and patient representatives. Consensus required ≥70% agreement on both the direction and strength of each recommendation.

**Results:** This guideline includes expanded indications for some vaccines in patients with RMDs, as well as guidance on whether to hold immunosuppressive medications or delay vaccination to maximize vaccine immunogenicity. Safe approaches to the use of live-attenuated vaccines in patients on immunosuppressive medications are also addressed. The overall quality of the evidence supporting the recommendations is low, and most recommendations are conditional.

**Conclusion:** Application of these recommendations should take into consideration patients' individual risk for vaccine-preventable illness and for disease flares, particularly if immunosuppressive medications are held for vaccination. Shared decision-making with patients is encouraged in clinical settings.

This summary was approved by the ACR Board of Directors on July 11, 2022. These recommendations are included in a full manuscript, which was published in Arthritis & Rheumatology and Arthritis Care and Research January 4, 2023.\*

### Expanded indications for specific vaccines in patients with RMDs on immunosuppression

For RMD patients aged  $\geq 65$  years, and RMD patients aged > 18 and < 65 years who are on immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination.

For patients with RMD aged <65 years who are on immunosuppressive medication, pneumococcal vaccination is strongly recommended.

For patients with RMD aged >18 years who are on immunosuppressive medication, administering the recombinant zoster vaccine is strongly recommended.

For patients with RMD aged >26 and <45 years who are on immunosuppressive medication and not previously vaccinated, vaccination against HPV is conditionally recommended.

© 2022 American College of Rheumatology. All rights reserved.

### Whether to give multiple vaccinations to RMD patients on the same day

For RMD patients, giving multiple vaccinations on the same day rather than giving each individual vaccination on a different day is conditionally recommended.

	Influenza vaccination	Other non-live attenuated vaccinations
Methotrexate	Hold methotrexate for 2 weeks after vaccination*	Continue methotrexate
Rituximab	Continue rituximab**	Time vaccination for when the next rituximab dose is due, and then hold rituximab for at least 2 weeks after vaccination
Immunosuppressive medications other than methotrexate and rituximab	Continue immunosuppressive medication	Continue immunosuppressive medication

### Medication management at the time of non-live attenuated vaccine administration

\*Hold only if disease activity allows. Non-rheumatology providers, e.g., general pediatricians and internists, are encouraged to give the influenza vaccination and then consult with the patient's rheumatology provider about holding methotrexate to avoid a missed vaccination opportunity.

\*\*Give influenza vaccination on schedule. Delay any subsequent rituximab dosing for at least 2 weeks after influenza vaccination if disease activity allows.

= Conditional recommendation

## Whether to give or defer non-live attenuated vaccinations in patients taking glucocorticoids, regardless of disease activity

	Influenza vaccination	Other non-live attenuated vaccinations
Prednisone ≤ 10 mg daily*	Give	Give
Prednisone > 10 mg and < 20 mg*	Give	Give
Prednisone ≥ 20 mg daily*	Give	Defer**

\*Or the equivalent dose of any other glucocorticoid formulation, or the equivalent pediatric dose \*\*Defer vaccination until glucocorticoids are tapered to the equivalent of prednisone < 20 mg daily



= Strong recommendation

= Conditional recommendation

For patients with RMD, giving non-live attenuated vaccinations is conditionally recommended regardless of their disease activity.

### Immunosuppressive medication management at the time of live-attenuated virus vaccine administration

For RMD patients who are on immunosuppressive medication, deferring live-attenuated vaccines is conditionally recommended.

For RMD patients, holding immunosuppressive medication for an appropriate period before (see Table below) and 4 weeks after live-attenuated virus vaccination is conditionally recommended.

Immunosuppressive medication	Hold before live-attenuated virus vaccine administration	Hold after live-attenuated virus vaccine administration
Glucocorticoids <sup>a</sup>	4 weeks	4 weeks
Methotrexate, azathioprine <sup>b</sup>	4 weeks	4 weeks
Leflunomide, mycophenolate mofetil,	4 weeks	4 weeks
calcineurin inhibitors, oral		
cyclophosphamide		
JAK inhibitors	1 week	4 weeks
TNF, IL17, IL12/23, IL23, BAFF/BLyS	1 dosing interval <sup>c</sup>	4 weeks
inhibitors		
IL6 pathway inhibitors	1 dosing interval <sup>d</sup>	4 weeks
IL1 inhibitors		
Anakinra	1 dosing interval <sup>d</sup>	4 weeks
Rilonacept	1 dosing interval <sup>d</sup>	4 weeks
Canakinumab	1 dosing interval <sup>d</sup>	4 weeks
Abatacept	1 dosing interval <sup>c</sup>	4 weeks
Anifrolumab	1 dosing interval <sup>c</sup>	4 weeks
Cyclophosphamide IV	1 dosing interval <sup>c</sup>	4 weeks
Rituximab	6 months	4 weeks
IVIG <sup>e</sup>		
300-400 mg/kg	8 months	4 weeks
1 gm/kg	10 months	4 weeks
2 gm/kg	11 months	4 weeks

JAK= Janus kinase; TNF=tumor necrosis factor; IL=interleukin; IVIG= intravenous immunoglobulin G; IV = intravenous

<sup>a</sup> for patients taking the equivalent of prednisone < 20 mg/day or < 2 mg/kg/day for patients weighing < 10 kg, or alternate-day glucocorticoid therapy (i.e., "low level immunosuppression" (14, 68), these low doses can be continued if vaccination is critical and the risk of a disease flare or adrenal insufficiency off glucocorticoids is high.

<sup>b</sup> for patients taking methotrexate  $\leq$  0.4 mg/kg/week or azathioprine  $\leq$  3 mg/kg/day ("low level" immunosuppression" (14, 68), hold times can be shortened if vaccination is critical and the risk of a disease flare off immunosuppression is high.

<sup>c</sup> for medications with more than one FDA-approved dosing interval, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks although it can be dosed every 1 or every 2 weeks).

<sup>d</sup> In children with autoinflammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic DMARDs are held is very high, shorter hold times can be considered if live-attenuated vaccination is critical.

<sup>e</sup> the recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efficacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay.

# When to administer live-attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero

Antenatal drug exposure in second	Within the first 6 months of life	After 6 months of life
or third trimester		
TNF inhibitor	Give rotavirus vaccine	
Rituximab	Do not give rotavirus vaccine	Give rotavirus vaccine

#### \* How to cite this article

Bass, A.R., Chakravarty, E., Akl, E.A., Bingham, C.O., Calabrese, L., Cappelli, L.C., et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases. Arthritis Care Res, 75: 449-464. https://doi.org/10.1002/acr.25045